Database: DESCAR-T (France)
Go back to France page
Type of database: registry.
Primary purpose: To assess the overall survival of patients eligible for CAR-T therapy. The secondary goals are: (i) to evaluate the overall survival of patients who have undergone CAR-T treatment, (ii) to assess the effectiveness of CAR-T in real-world settings, and (iii) to examine both the short-term and long-term safety profile of CAR-T in real-life conditions.
Sponsor, manager, or home institution: LYSARC.
Type of information: longitudinal. Comprehensive data on patients treated with Chimeric Antigen Receptor T (CAR-T) cells for hematological malignancies. It includes patient demographics (age, gender, weight), clinical characteristics (tumor types, disease stage, ECOG performance status), treatment details (pre- and post-CAR-T protocols, infusion specifics), adverse events (toxicity and side effects), relapse data, and vital status (survival outcomes and overall survival rates). Click here to learn more.
Source of information: Medical records from participating hospitals in France.
Data level: patient level.
Number of records: 748 as of April 2021.
Date range: 2019 onwards.
Cancer areas of interest: C81-C96: Cancers of the blood and immune system. Click here to learn more.
Data access: not publicly available. Data requires a grant proposal to be accessed. Instructions to request data for restricted content: Click here to access in "Contact" section.
Contact information: Click here to learn more.
